#Mace2
good catch -- & honestly that alone calls everything in the paper into question: N501 variants that don't alternatively change Q498 to something aromatic (cf. www.ncbi.nlm.nih.gov/pmc/articles...) are unable to bind mACE2 & this is the sole hard barrier for mouse infxn -- so if it could use HRH1...
A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures
Coronaviruses are prone to emergence into new host species most recently evidenced by SARS-CoV-2, the causative agent of the COVID-19 pandemic[] . Small animal models that recapitulate SARS-CoV-2 dise...
www.ncbi.nlm.nih.gov
July 16, 2024 at 11:26 PM
April 13, 2025 at 5:25 PM
March 24, 2025 at 7:00 PM
March 18, 2025 at 7:10 PM
A small handful of Commissions. Yeah, I still have the ol' Blogger for quite some time. PS: Don't worry about the warnings, there's no NSFW in the link.
mace2-0.blogspot.com/2025/01/more...
MORE COMMISSIONS I PAID FOR (July - December 2024 edition)
SUP! It's that time again where I paid rando artists I followed online where I told them to draw. So there's only a few commissions plus on...
mace2-0.blogspot.com
January 26, 2025 at 5:00 AM
Made a couple blogs showing off some commissions I paid for, last year.
(Jan-June 2023) mace2-0.blogspot.com/2023/07/some...
(July-Dec 2023) mace2-0.blogspot.com/2024/01/some...
January 23, 2024 at 4:16 PM
A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures https://www.biorxiv.org/content/10.1101/2020.05.06.081497v1
A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures
Coronaviruses are prone to emergence into new host species most recently evidenced by SARS-CoV-2, the causative agent of the COVID-19 pandemic. Small animal models that recapitulate SARS-CoV-2 disease are desperately needed to rapidly evaluate medical countermeasures (MCMs). SARS-CoV-2 cannot infect wildtype laboratory mice due to inefficient interactions between the viral spike (S) protein and the murine ortholog of the human receptor, ACE2. We used reverse genetics to remodel the S and mACE2 binding interface resulting in a recombinant virus (SARS-CoV-2 MA) that could utilize mACE2 for entry. SARS-CoV-2 MA replicated in both the upper and lower airways of both young adult and aged BALB/c mice. Importantly, disease was more severe in aged mice, and showed more clinically relevant phenotypes than those seen in hACE2 transgenic mice. We then demonstrated the utility of this model through vaccine challenge studies in immune competent mice with native expression of mACE2. Lastly, we show that clinical candidate interferon (IFN) lambda-1a can potently inhibit SARS-CoV-2 replication in primary human airway epithelial cells in vitro , and both prophylactic and therapeutic administration diminished replication in mice. Our mouse-adapted SARS-CoV-2 model demonstrates age-related disease pathogenesis and supports the clinical use of IFN lambda-1a treatment in human COVID-19 infections. ### Competing Interest Statement M.D.B and I.C.C. are employees, and J.S.G is the founder and a board member, of Eiger BioPharmaceuticals, Inc., which produces peg-IFN-λ1.
www.biorxiv.org
May 8, 2020 at 11:20 PM
Commission for Mace2-0. it's Shanks. From One Piece!
March 24, 2026 at 9:46 AM